The lowest of low hanging fruit would be to just assay for insulin before and after giving Zantrene in the EMD AML trial. The patients in Stratum 2 are very likely to have Type 2 diabetes given their age and their unsuitability for high intensity chemotherapy - my rough guess is between 30-50% will be either diabetic or pre-diabetic.
We will be collecting blood from the patients anyway so it is just a matter of running some of the blood through a standard assay for insulin. It would likely only cost a couple of hundred dollars extra per patient to assay for insulin even taking into account the usual inflated clinical trial costs. Imagine if we find that Zantrene does positively impact insulin secretion in humans at low doses.
Ann: Quarterly Activity Report & Appendix 4C, page-40
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
-0.025(1.34%) |
Mkt cap ! $313.3M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.91 | $1.81 | $257.6K | 138.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 26825 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 759 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |